This resulted in the downregulation of the MAPK/ERK and PI3/Akt signaling pathways, decreased cell–ECM interactions and cell migration, and ultimately inhibited tumor progression and potential tumor resistance following treatment (91). This evidence concerns the gene AKT1 and neoplasm.